Investigational drug CT-01 for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new experimental drug called CT-01, given alone or with another drug (everolimus), for people with intermediate or advanced liver cancer that has not responded to standard treatments. The goal is to see if the combination can shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of intermediate or advanced liver cancer (hepatocellular carcinoma).
- Your liver function must be relatively good (Child-Pugh class A).
- You must have tried at least one standard treatment for liver cancer and it didn't work or you couldn't tolerate it.
- You must be physically able to care for yourself (ECOG score 0 or 1) and have at least one measurable tumor in the liver.
- You must not have had a liver transplant, another active cancer (except certain skin cancers), or unstable bleeding in the stomach or esophagus.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ACE723, which is designed to specifically attack liver cancer cells while sparing healthy cells. It is for people with advanced liver cancer that has not responded to or has worsened after standard treatments that included immunotherapy.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy and a procedure called TACE (which blocks the blood supply to the tumor) for people with advanced liver cancer. It aims to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy pill (regorafenib) for people with advanced liver cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a new drug called BB102 for people with liver cancer (HCC) that has grown after at least one previous treatment. The drug targets a specific protein (FGF19) that may be fueling the cancer, and doctors want to see if it can shrink tumors or slow the disease.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This early-phase trial tests an experimental drug called CD-801 given through an IV for people with advanced liver cancer (HCC) that cannot be surgically removed and has not responded to or is not suitable for standard treatments. The goal is to see if CD-801 is safe and helps shrink tumors.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.